Document is current
Any future updates will be listed below
-
Authors
Yong, Dongeun https://orcid.org/0000-0002-1225-8477
Lee, Hakbae https://orcid.org/0000-0002-4615-2646
Min, Hyung-Gyu https://orcid.org/0000-0002-7944-6130
Kim, Kyungnam https://orcid.org/0000-0002-4889-3069
Oh, Hyun-Seok https://orcid.org/0000-0001-8560-7132
Chu, Min Kyung https://orcid.org/0000-0001-6221-1346
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2022R1A2C1091767)
- License Information
-
More Information
Article History
Received: 28 February 2022
Accepted: 4 January 2023
First Online: 12 January 2023
Competing interests
: Author MKC was a site investigator for a multicenter trial sponsored by Biohaven Pharmaceuticals, Allergan Korea, and the Ildong Pharmaceutical Company. He has received lecture honoraria from Eli Lilly and Company, Handok-Teva, and Ildong Pharmaceutical Company over the past 36 months. He received grants from Yonsei University College of Medicine (6–2021-0229), the Korea Health Industry Development Institute (KHIDI) (HV22CO106) and National Research Foundation of Korea (2022R1A2C1091767). Author HSO is employed by CJ Bioscience Inc. The other authors declare that they have no competing interests.
